PDAC - PANCREATIC DUCTAL ADENOCARCINOMA

This study tests a new drug called daraxonrasib to see if it can delay or prevent pancreatic cancer from returning after surgery and chemotherapy. About 500 adults who have had their pancreatic cancer removed will be randomly assigned to receive the drug or just be watched. The g…

This study tests a new drug called daraxonrasib, which targets a common cancer-driving protein (RAS). It is given alone or with standard chemotherapy to people with metastatic pancreatic cancer that has spread. The goal is to see if the new drug helps people live longer or slows …

This early-stage study tests a new drug called TJ033721 (givastomig) in people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 330 partici…

This study tests whether giving a short course of two medicines (hydrocortisone and octreotide) plus using a patch made from the patient's own tissue during surgery can lower the risk of serious complications after Whipple surgery. The trial includes 400 adults with a small pancr…

This early-stage trial tests a new drug called ALTA3263 in adults with advanced solid tumors (like pancreatic, lung, or colorectal cancer) that have a KRAS mutation. The main goals are to check safety and find the right dose. About 188 people whose cancer has worsened after stand…

This early-phase study tests a new drug called BBO-11818 in people with advanced solid tumors (lung, pancreatic, colorectal, or others) that have a specific KRAS gene mutation. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Abo…

This study tests a new drug called TNG462, given with other cancer medicines, for people with pancreatic or lung cancer that has a specific genetic change (MTAP loss). The goal is to find safe doses and see if the combination shrinks tumors. About 183 adults with advanced cancer …

This study looks at whether closely monitoring and controlling blood sugar levels can help people with pancreatic cancer who are receiving chemotherapy. About 50 participants will wear a continuous glucose monitor and be randomly assigned to either tight blood sugar control or st…

This study tests whether adding a new type of targeted nanocell therapy to standard chemotherapy can help people with metastatic pancreatic cancer live longer. The nanocells are designed to deliver a powerful drug directly to cancer cells while also boosting the immune system. Ab…

This early-phase trial tests a new drug called AVA6103 in about 144 people with advanced solid tumors (like pancreatic, stomach, or lung cancer) that have not responded to standard treatments. The drug is designed to activate only inside tumors to kill cancer cells while limiting…

This study aims to develop a non-invasive breath test to detect pancreatic cancer earlier. Researchers will measure tiny molecules in the breath of 1,005 participants, including those with pancreatic cancer, diabetes, or non-specific symptoms. The goal is to help doctors identify…

This study is testing a new breath test to find pancreatic cancer earlier. The test looks for tiny molecules made by cancer cells that are released in a person's breath. Researchers will collect breath samples from about 6,000 people who have been referred for possible pancreatic…

This study enrolls 5,000 people at high risk for pancreatic cancer to collect blood, pancreatic juice, and medical images over 10 years. Researchers will use these samples to develop and validate tests for early detection, including AI-assisted analysis. Participants must be 18 o…

This study aims to grow mini-tumors (organoids) from small biopsy samples of pancreatic cancer. Researchers will check if these lab-grown organoids match the original tumor's genes and markers. If successful, this could help doctors test treatments on a patient's own tumor cells …